Prurigo nodularis
☆ Ninu awọn abajade 2022 Stiftung Warentest lati Jẹmánì, itẹlọrun alabara pẹlu ModelDerm jẹ kekere diẹ ju pẹlu awọn ijumọsọrọ telemedicine isanwo.
References
Prurigo nodularis jẹ ipo awọ-ara ti o pẹ to ti o ni ijuwe nipasẹ ọpọlọpọ awọn bumps ati nodules, ti a rii nigbagbogbo lori awọn ẹya ita ti awọn apa ati awọn ẹsẹ. Awọn bumps wọnyi le yatọ ni awọ lati ara-toned si Pink ati ki o jẹ yun pupọ. Wọn le ni ipa lori awọn eniyan ti ọjọ-ori eyikeyi ati nigbagbogbo ni asopọ pẹlu awọn ipo awọ ara miiran ti o fa nyún onibaje, bii atopic dermatitis. Awọn aṣayan itọju pẹlu awọn oogun egboogi-itch ti o lagbara, awọn oogun ti o ni ipa lori eto ajẹsara, ati awọn oogun ti o fojusi eto aifọkanbalẹ. Ṣiṣakoso nodularis prurigo nigbagbogbo jẹ itọju ailera igba pipẹ.
Prurigo nodularis is a chronic disorder of the skin that is classically seen as multiple, firm, flesh to pink colored papules, plaques and nodules commonly located on the extensor surfaces of the extremities. The lesions are very pruritic and can occur in any age group. It is commonly associated with another disease such as atopic dermatitis or any dermatoses associated with chronic pruritus. The therapeutic approach is wide-arrayed ranging from treatments that act as - potent antipruritics, immunomodulators, and neuromodulators. Treatment in an established case is prolonged and improving patient compliance with education and counseling is important.
Prurigo nodularis is a chronic disorder of the skin that is classically seen as multiple, firm, flesh to pink colored papules, plaques and nodules commonly located on the extensor surfaces of the extremities. The lesions are very pruritic and can occur in any age group. It is commonly associated with another disease such as atopic dermatitis or any dermatoses associated with chronic pruritus. The therapeutic approach is wide-arrayed ranging from treatments that act as - potent antipruritics, immunomodulators, and neuromodulators. Treatment in an established case is prolonged and improving patient compliance with education and counseling is important.
Itọju maa n jẹ lilo awọn ipara tabi awọn abẹrẹ ti awọn sitẹriọdu lori agbegbe ti o kan. Ni awọn ọran ti o nira tabi alagidi, awọn itọju bii itọju ailera ina tabi awọn oogun ti o dinku eto ajẹsara le nilo. Thalidomide ati lenalidomide jẹ awọn aṣayan fun awọn ọran ti o nira, ṣugbọn wọn le ni awọn ipa ẹgbẹ to ṣe pataki. Awọn itọju titun (opioid receptor antagonists, neurokinin-1 receptor antagonists) fihan ileri ni itọju prurigo nodularis pẹlu awọn ipa ẹgbẹ diẹ ti a fiwe si thalidomide tabi lenalidomide.
Treatment typically relies on the use of topical or intralesional steroids, though more severe or recalcitrant cases often necessitate the use of phototherapy or systemic immunosuppressives. Thalidomide and lenalidomide can both be used in severe cases; however, their toxicity profile makes them less favorable. Opioid receptor antagonists and neurokinin-1 receptor antagonists represent two novel families of therapeutic agents which may effectively treat PN with a lower toxicity profile than thalidomide or lenalidomide.
Treatment typically relies on the use of topical or intralesional steroids, though more severe or recalcitrant cases often necessitate the use of phototherapy or systemic immunosuppressives. Thalidomide and lenalidomide can both be used in severe cases; however, their toxicity profile makes them less favorable. Opioid receptor antagonists and neurokinin-1 receptor antagonists represent two novel families of therapeutic agents which may effectively treat PN with a lower toxicity profile than thalidomide or lenalidomide.
Chronic prurigo jẹ ipo awọ ara ti o ni ijuwe nipasẹ irẹwẹsi pipẹ (ti o gun ju ọsẹ 6 lọ) , awọn ọgbẹ awọ ti o ni ibatan, ati itan-kikan nigbagbogbo. O kan neuroinflammation ati fibrosis ninu awọ ara.
Chronic prurigo (CPG) is a neuroinflammatory, fibrotic dermatosis that is defined by the presence of chronic pruritus (itch lasting longer than 6 weeks), scratch-associated pruriginous skin lesions and history of repeated scratching.
Chronic prurigo (CPG) is a neuroinflammatory, fibrotic dermatosis that is defined by the presence of chronic pruritus (itch lasting longer than 6 weeks), scratch-associated pruriginous skin lesions and history of repeated scratching.
Prurigo nodularis jẹ iṣoro awọ-ara ti o pẹ to ti samisi nipasẹ awọn nodules nyún. A ko mọ pato ohun ti o fa, ṣugbọn o dabi pe awọn ajẹsara ati awọn oran-ara ni ipa kan ninu iyipo-iyọ-iṣan. Ni bayi, ko si awọn itọju eyikeyi ti a fọwọsi nipasẹ US FDA pataki fun prurigo nodularis.
Prurigo nodularis is a long-lasting skin problem marked by itchy nodules. We don't know exactly what causes it, but it seems that immune and nerve issues play a role in the itch-scratch cycle. Right now, there aren't any treatments approved by the US FDA specifically for prurigo nodularis.
Prurigo nodularis is a long-lasting skin problem marked by itchy nodules. We don't know exactly what causes it, but it seems that immune and nerve issues play a role in the itch-scratch cycle. Right now, there aren't any treatments approved by the US FDA specifically for prurigo nodularis.
○ Itọju - Oògùn OTC
Fifọ agbegbe ọgbẹ pẹlu ọṣẹ ko ṣe iranlọwọ rara ati pe o le jẹ ki o buru sii. Awọn ikunra sitẹriọdu OTC le ṣe iranlọwọ lati yọkuro awọn aami aisan naa, ṣugbọn wọn nigbagbogbo nilo lati lo fun awọn ọsẹ pupọ lati ni ilọsiwaju. Tẹsiwaju lati mu awọn antihistamines tun ṣe iranlọwọ lati yọkuro nyún naa.
#OTC steroid ointment
#OTC antihistamine
○ Itọju
#Intralesional triamcinolone injection